[{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CD24Fc","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rabeximod","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Not Applicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Kezar Life Sciences \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Cowen"},{"orgOrder":0,"company":"Salzman Group","sponsor":"Kalytera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Salzman Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Salzman Group \/ Kalytera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Salzman Group \/ Kalytera Therapeutics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"OSE-127","moa":"IL-7R","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Servier"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"IMVT-1401","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.14000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ SVB Leerink"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Telitacicept","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Not Applicable"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Patch","sponsorNew":"AFYX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Affibody","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"ABY-035","moa":"IL-17","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Affibody \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Kancera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"KAND567","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kancera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kancera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kancera \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"NKTR-358","moa":"IL-2","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ATI-450","moa":"Mapk2","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"NKTR-358","moa":"IL-2","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"ABBV-3373","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"Fc receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Momenta Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ALPN-101","moa":"ICOS","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0.87,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.87,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ AbbVie","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Immune Sciences \/ AbbVie"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"IMVT-1401","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Private Placement","leadProduct":"ALPN-101","moa":"ICOS","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Immune Sciences \/ Omega Funds"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"Fc receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Momenta Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Guggenheim Securities, LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"DM199","moa":"Kallikrein-1","graph1":"Immunology","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"DiaMedica Therapeutics \/ Guggenheim Securities, LLC","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica Therapeutics \/ Guggenheim Securities, LLC"},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"IMVT-1401","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PRV-015","moa":"IL-15","graph1":"Immunology","graph2":"Phase II","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Not Applicable"},{"orgOrder":0,"company":"Beyond Celiac","sponsor":"Provention Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"IL-15","graph1":"Immunology","graph2":"Phase II","graph3":"Beyond Celiac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Beyond Celiac \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Celiac \/ Provention Bio"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rabeximod","moa":"TNF","graph1":"Immunology","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Celiac Disease Foundation","sponsor":"Provention Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"IL-15","graph1":"Immunology","graph2":"Phase II","graph3":"Celiac Disease Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celiac Disease Foundation \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Celiac Disease Foundation \/ Provention Bio"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"NKTR-358","moa":"IL-2","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"GPCR Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Burixafor","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"TaiGen Biotechnology \/ GPCR Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"TaiGen Biotechnology \/ GPCR Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atacicept","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0.70999999999999996,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.70999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Vera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Vera Therapeutics"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"SynAct Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"AP1189","moa":"Il-6","graph1":"Immunology","graph2":"Phase II","graph3":"SynAct Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"suspension","sponsorNew":"SynAct Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SynAct Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Affibody","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"ABY-035","moa":"IL-17A","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affibody \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Not Applicable"},{"orgOrder":0,"company":"XOMA","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Mezagitamab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"XOMA","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"","sponsorNew":"XOMA \/ Takeda","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Takeda"},{"orgOrder":0,"company":"ExeGi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"EXE-346","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ExeGi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ExeGi \/ Not Applicable"},{"orgOrder":0,"company":"Groupe Persavita","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Groupe Persavita","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Groupe Persavita \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Groupe Persavita \/ Not Applicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"RSLV-132","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Resolve Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Not Applicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"AC BioScience","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"LX2931","moa":"S1P lyase","graph1":"Immunology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ AC Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ AC Bioscience"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSL Vifor \/ ChemoCentryx","highestDevelopmentStatusID":"8","companyTruncated":"CSL Vifor \/ ChemoCentryx"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"WuXi STA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ WuXi STA","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ WuXi STA"},{"orgOrder":0,"company":"Longeveron","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Lomecel-B","moa":"VEGF","graph1":"Immunology","graph2":"Phase II","graph3":"Longeveron","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"intravenous infusion","sponsorNew":"Longeveron \/ Renaissance Capital","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Renaissance Capital"},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"RVT-1401","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cantor Fitzgerald & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.23999999999999999,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Cantor Fitzgerald & Co","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Cantor Fitzgerald & Co"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Transmucosal","sponsorNew":"AFYX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"4SC AG","sponsor":"Immunic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","graph1":"Immunology","graph2":"Phase II","graph3":"4SC AG","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Oral Tablet","sponsorNew":"4SC AG \/ Immunic","highestDevelopmentStatusID":"8","companyTruncated":"4SC AG \/ Immunic"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","graph1":"Immunology","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Immunology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dersimelagon","moa":"MC1R","graph1":"Immunology","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Belumosudil","moa":"ROCK 2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Transmucosal","sponsorNew":"AFYX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Momenta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"Fc receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Momenta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Momenta Pharmaceuticals"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"aMoon","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Series A Financing","leadProduct":"Neihulizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ aMoon","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ aMoon"},{"orgOrder":0,"company":"William Harvey Research Institute","sponsor":"Cyxone AB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Rabeximod","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"William Harvey Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"William Harvey Research Institute \/ Cyxone","highestDevelopmentStatusID":"8","companyTruncated":"William Harvey Research Institute \/ Cyxone"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"PI3K delta","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Revolo Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"\u20181805","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Northway Biotechpharma \/ Revolo Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Northway Biotechpharma \/ Revolo Biotherapeutics"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0.93999999999999995,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.93999999999999995,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Biogen"},{"orgOrder":0,"company":"Immunovant","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"IMVT-1401","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.20000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Roivant Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Roivant Sciences"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Corticosteroid","moa":"CD40","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.59999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.59999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Incyte","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ Incyte"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"LSD1","graph1":"Immunology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Lyophilized Powder For Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"AXA1125","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Incyte","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ Incyte"},{"orgOrder":0,"company":"Xencor","sponsor":"Zenas BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Obexelimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Xencor","amount2":0.47999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.47999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Zenas BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Zenas BioPharma"},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Gumokimab","moa":"IL-17A","graph1":"Immunology","graph2":"Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ Not Applicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"\u20181805","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"PRT120","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prota Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"XT-150","moa":"IL-10","graph1":"Immunology","graph2":"Phase II","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Xalud Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xalud Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","graph1":"Immunology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Not Applicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"BIOKEY","sponsor":"NeuCen BioMed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"CEN501","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"BIOKEY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Strip","sponsorNew":"BIOKEY \/ NeuCen BioMed","highestDevelopmentStatusID":"8","companyTruncated":"BIOKEY \/ NeuCen BioMed"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dazodalibep","moa":"CD40","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"KIT D816V","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"PRT120","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Prota Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Lyophilized Powder For Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"cKIT","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"PI3K delta","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"UB-221","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Affibody","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Izokibep","moa":"IL-17 A receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inmagene Biopharmaceuticals \/ Affibody AB","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Affibody AB"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Not Applicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ANX005","moa":"C1q","graph1":"Immunology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"cKIT","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"cKIT","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"cKIT","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cilnidipine","moa":"Calcium channel","graph1":"Immunology","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Aisa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"UB-221","moa":"IgE production","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dazodalibep","moa":"CD40","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"KP104","moa":"Complement system","graph1":"Immunology","graph2":"Phase II","graph3":"Kira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"National Research Council of Canada Industrial Research Assistance Program","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"QBKPN SSI","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Qu Biologics Inc \/ National Research Council of Canada Industrial Research Assistance Program","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ National Research Council of Canada Industrial Research Assistance Program"},{"orgOrder":0,"company":"AllerPops","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AllerPops","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"AllerPops","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Lollipop","sponsorNew":"AllerPops \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AllerPops \/ Not Applicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Telitacicept","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Not Applicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"KIT D816V","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"FT011","moa":"TGF beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Regimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"RGI-2001","moa":"Tregs","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ Not Applicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"T\/B Cell","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Axatilimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Axatilimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Sonelokimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Regimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"RGI-2001","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Daxdilimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Dazodalibep","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Belimumab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"NDI-034858","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":6,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":6,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"NDI-034858","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":6,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":6,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Takeda"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"EB06","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"FT011","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Rezpegaldesleukin","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oscotec","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cevidoplenib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Not Applicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Apraglutide","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"RRx-001","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"EpicentRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Not Applicable"},{"orgOrder":0,"company":"Regimmune","sponsor":"San Fu Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"RGI-2001","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regimmune \/ San Fu Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ San Fu Biotech"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Daxdilimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SHL Medical AG","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Adalimumab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"SHL Medical AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"SHL Medical AG \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SHL Medical AG \/ MoonLake Immunotherapeutics"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Fidelity Management & Research","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"DNTH103","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Dianthus Therapeutics \/ Fidelity Management & Research","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Fidelity Management & Research"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Human IgG4 Monoclonal Antibody","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"GLPG3667","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Not Applicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Elsubrutinib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zunsemetinib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cilnidipine","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Aisa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Talaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"TOUR006","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Tourmaline Bio \/ Talaris Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Talaris Therapeutics"},{"orgOrder":0,"company":"Molecure","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"OATD-01","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Molecure \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Galapagos"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Sonelokimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.25,"dosageForm":"Injectable\/Injection","sponsorNew":"MoonLake Immunotherapeutics \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake Immunotherapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Daxdilimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Molecure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"OATD-01","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Molecure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Not Applicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Sonelokimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Vilamakitug","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LNK01001","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LNK01001","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"GLPG3667","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Not Applicable"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"TOUR006","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Tourmaline Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Not Applicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"MaaT033","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NDI-034858","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Scleroderma Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Scleroderma Research Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Scleroderma Research Foundation"},{"orgOrder":0,"company":"ClinConnect","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"AZD1656","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"ClinConnect","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ClinConnect \/ Conduit Pharma","highestDevelopmentStatusID":"8","companyTruncated":"ClinConnect \/ Conduit Pharma"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"EP262","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Immunoforge","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Froniglutide","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunoforge \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunoforge \/ Not Applicable"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Tourmaline Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"TOUR006","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Talaris Therapeutics \/ Tourmaline Bio","highestDevelopmentStatusID":"8","companyTruncated":"Talaris Therapeutics \/ Tourmaline Bio"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"TOUR006","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Acuta Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Acuta Capital Partners"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Cartesian Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Descartes-08","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Selecta Biosciences \/ Cartesian Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Cartesian Therapeutics"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"Descartes-08","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Selecta Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Leerink Partners"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"FT011","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zunsemetinib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"KYV-101","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"MaaT033","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Axatilimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Axatilimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"TOUR006","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Not Applicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Arsenic Trioxide","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ ABO Securities"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"PRT120","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"","sponsorNew":"Prota Therapeutics \/ SPRIM Global Investments","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"TOUR006","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Jefferies"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"DNTH103","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"Dianthus Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"TOUR006","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Jefferies"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0.32000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0.37,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"FT011","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ARS Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"DNTH103","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dianthus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Oscotec","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cevidoplenib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Not Applicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Not Applicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Molecure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"OATD-01","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Molecure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Efgartigimod Alfa","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Apraglutide","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Acazicolcept","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.12,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Abbvie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Immune Sciences \/ Abbvie Inc"},{"orgOrder":0,"company":"BioSenic","sponsor":"Gestys Sant\u00e9 Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Arsenic Trioxide","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"BioSenic \/ Gestys Sant\u00e9 Biotech","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Gestys Sant\u00e9 Biotech"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0.46000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Brepocitinib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Roivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"KYV-101","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"LP-003","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longbio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CYP-001","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"LP-003","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longbio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Mezagitamab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"GlucoCorticoid","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alentis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alentis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Batoclimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Kinevant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Namilumab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roivant Sciences \/ Kinevant Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Kinevant Sciences"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"Tegoprubart","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Descartes-08","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ruxoprubart","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CPL\u2019 116","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Celon Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Molecure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"OATD-01","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Molecure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"}]
Find Immunology Drugs in Phase II Clinical Development
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.